Subtype
Gastroesophageal Junction Carcinoma
CI-CAN-00005404Explore in graph →
231 active trials9 approved drugs25 evidence items
- NCIt
- C203675
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005404Explore in graph →
Clinical trials
706 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (86)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07621484 | HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer | not yet recruiting | Phase 2 | 48 | Shanghai Changzheng HospitalOTHER | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07685704 | Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study | not yet recruiting | Phase 2 | 46 | Zhifeng Zhao, PhDOTHER | 1 | Jul 6, 2026 |
| clinicaltrials |
| NCT05709574 | Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer | active not recruiting | Phase 2 | 11 | University of ArizonaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05836584 | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer | active not recruiting | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07139951 | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence | enrolling by invitation | Phase 2 | 16 | Mayo ClinicOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | recruiting | Phase 2 | 72 | Dan ZandbergOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04929392 | Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer | active not recruiting | Phase 2 | 3 | City of Hope Medical CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06038578 | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | recruiting | Phase 2 | 146 | Toray Industries, IncINDUSTRY | 3 | Jun 23, 2026 | clinicaltrials |
| NCT07658872 | Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma | not yet recruiting | Phase 2 | 120 | Sichuan UniversityOTHER | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07655661 | Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. | not yet recruiting | Phase 2 | 52 | Ming LiuOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07655024 | TAIC FOLFOX for Locally Advanced G/GEJA(TFLAG) | recruiting | Phase 2 | 31 | Guang'anmen Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04739202 | Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)(IMMUNOGAST) | completed | Phase 2 | 54 | Hospices Civils de LyonOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07621562 | Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer | not yet recruiting | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07610629 | Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer(RA-A-NP) | not yet recruiting | Phase 2 | 50 | Henan Cancer HospitalOTHER_GOV | 1 | May 28, 2026 | clinicaltrials |
| NCT05977998 | A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07603349 | Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 / Phase 3 | 405 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04984733 | Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer(ELEVATE) | completed | Phase 2 | 13 | University of SouthamptonOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06251973 | A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer | active not recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07432295 | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | recruiting | Phase 2 | 180 | I-Mab Biopharma US LimitedINDUSTRY | 3 | May 14, 2026 | clinicaltrials |
| NCT04034251 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT07007182 | Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer | recruiting | Phase 2 | 54 | Jinbo YueOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07178808 | PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER | recruiting | Phase 2 | 30 | Banner HealthOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06846346 | Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma(GRACIE) | recruiting | Phase 2 | 88 | UNICANCEROTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07551362 | Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer(DUET-GEJ) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07353684 | Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer | recruiting | Phase 2 | 49 | Beijing Friendship HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05480384 | Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction | active not recruiting | Phase 2 | 1 | Brown UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07040059 | A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | terminated | Phase 1 / Phase 2 | 2 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03161522 | Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07529613 | Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma(T-DXd_HER2Low) | completed | Phase 1 / Phase 2 | 30 | National Cancer Center Hospital EastOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05745857 | Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas(SLURP) | recruiting | Phase 2 | 25 | University Medical Center GroningenOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05567835 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer(TOGAR) | terminated | Phase 2 | 3 | Baylor College of MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05927857 | Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . | recruiting | Phase 1 / Phase 2 | 45 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05034887 | Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma | active not recruiting | Phase 2 | 64 | National Cancer Center Hospital EastOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05753306 | Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07507526 | A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer(DTP-HER2) | not yet recruiting | Phase 2 | 76 | Sun Yat-sen UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06461910 | Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 30 | Zekuan XuOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03686488 | TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | completed | Phase 2 | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04430738 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | active not recruiting | Phase 2 | 40 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT03008278 | Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04762953 | Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis(STOPGAP) | active not recruiting | Phase 2 | 40 | University of California, IrvineOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07266025 | Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study(CATALIS) | not yet recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 0 | Jan 27, 2026 | clinicaltrials |
| NCT03539822 | Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies(CAMILLA) | recruiting | Phase 1 / Phase 2 | 117 | Anwaar SaeedOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03257163 | Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer | active not recruiting | Phase 2 | 40 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07332533 | A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer | not yet recruiting | Phase 2 / Phase 3 | 490 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Jan 12, 2026 | clinicaltrials |
| NCT07334431 | Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer | recruiting | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04028167 | Induction FLOT With CROSS CRT for Esophageal Cancer | active not recruiting | Phase 2 | 40 | University of Colorado, DenverOTHER | 1 | Jan 9, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 7, 2026source: clinicaltrials